openPR Logo
Press release

COVID-19: Potential Impact on Pneumonia Vaccine Market to Hit Valuation of $10.21 Billion by 2025 | Panacea Biotec Limited, Pfizer Inc

08-07-2020 12:33 PM CET | Health & Medicine

Press release from: Allied Market Research

Pneumonia Vaccine Market

Pneumonia Vaccine Market

UPDATE AVAILABLE ON-DEMAND

The global pneumonia vaccine market is expected to reach $10,215 million by 2025, registering a CAGR of 5% from 2018 to 2025, in terms of value.

Global Pneumonia Vaccine Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly changing market scenarios and their impact are covered in the report.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/2730

Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, virus, or fungi; however, bacterial pneumonia is the most common form occurring in adults.

Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, which results in filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at greatest risk of serious pneumococcal infections and even death.

Pneumonia vaccines are primarily administered to children less than 2-years old and adults aged 65 years and older. This vaccine helps individuals provide immunization against 13 types of pneumococcal bacteria that causes infection in the lungs.

The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high costs associated with development of such vaccines restrain the market growth. Development of protein-based combination pneumococcal vaccines is expected to offer lucrative opportunities for the expansion of this market during the forecast period.

Based on type, pneumococcal conjugate vaccine (PCV) is expected to maintain its dominant (more than half of the market share in 2017) position during the analysis period as it is been widely prescribed as compared to pneumococcal polysaccharide vaccine (PPV).

Based on product, the Prevnar 13 segment held the major market share in 2017 and is expected to dominate the market throughout the forecast period, owing to the wide usage and its efficiency in pneumonia prevention.

Based on distribution channel, the distribution partner companies segment held majority of the market share in 2017, owing to the wide coverage of the private entities. This segment is expected to dominate the market during the forecast period due to majority of private vaccines purchases which are comparatively expensive are distributed from these companies. Hence, the distribution partner companies hold larger share.

Based on sector, the private sector dominates the overall market for pneumonia vaccines and is expected to dominate the market throughout the forecast period due to the higher prices of the vaccine in the private market.

North America accounted for nearly three-fifth of the global market in 2017 and is expected to remain dominant throughout the forecast period. This is attributed to the higher prevalence in the developing countries such as India and China, increase in government healthcare expenditure, rise in demand for better healthcare, and surge in number of childbirths in the region. Moreover, government support and development of protein-based combination pneumococcal vaccines are the factors expected to present new growth opportunities to the players in this market

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2730

The Major Key Players Are:

Glaxosmithkline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience, and Walvax Biotechnology Co., Ltd.

Key Findings of the Pneumonia Vaccine Market:

• The pneumococcal conjugate vaccine (PCV) segment is expected to grow with a CAGR of 5.1% from 2017 to 2025.
• Prevnar 13 vaccine is expected to be the fastest growing product with a CAGR of 5.1%.
• The distribution partner companies held approximately half of the global market share and is expected to remain dominant throughout the forecast period.
• The private segment held more than threeforth share in the global market and is expected to remain dominant throughout the forecast period.
• Asia-Pacific is expected to be the fastest growing region, registering a CAGR of 6.6% during the forecast period.

Contact:

David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release COVID-19: Potential Impact on Pneumonia Vaccine Market to Hit Valuation of $10.21 Billion by 2025 | Panacea Biotec Limited, Pfizer Inc here

News-ID: 2106675 • Views: 573

More Releases from Allied Market Research

Premise Cable Market 2020–2027: Market Share, Emerging Trends, Top Impacting F …
Allied Market Research published a new report, titled, "Premise Cable Market By Type (Copper Cable and Fiber Optic Cable) and Application (Industrial, Broadcast, Enterprise, IT & Network security and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027". The report provides a detailed study of the global premise cable market covering a number of important aspects such as current market scenario, estimates, top investment pockets, recent trends, changing dynamics, and vibrant forces
ASIC Chip Market 2020–2027: Recent Developments, Market Share, Top Impacting F …
Allied Market Research published a new report, titled, "ASIC Chip Market By Type (Full Custom, Semi- Based Custom, and Programmable Logic Devices) and Application (Aerospace Subsystem & Sensor, Wireless Communication, Medical Instrumentation, Telecommunication Products, Consumer Electronics, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027". The report provides a detailed study of the global ASIC Chip market covering a number of important aspects such as current market scenario, estimates, top investment
Class D Audio Amplifier Market 2020-2027: Current Trends, Market Size, Share, Se …
Allied Market Research published a new report, titled, "Class D Audio Amplifier Market By Amplifier Type (Mono-Channel, 2-Channel, 4-Channel, 6-Channel, and Others), Device (Television Sets, Home Audio Systems, Desktop & Laptops, Automotive Infotainment Systems, and Others), and End use (Automotive, Consumer Electronics, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027". The report provides a detailed study of the global class D audio amplifier market covering a number of important aspects
Smart Greenhouse Market 2020–2027: Recent Developments, Market Share, Top Impa …
Allied Market Research published a new report, titled, "Smart Greenhouse Market By Type (Hydroponic and Non-Hydroponic), Component (HVAC Systems, LED Grow Lights, Irrigation System, Valves & Pumps, Sensor & Control System, and Others), and End User (Commercial Growers, Research & Educational Institutes, Retail Gardens, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027". The report provides a detailed study of the global smart greenhouse market covering a number of important aspects

All 5 Releases


More Releases for Pneumonia

Global Pneumonia Therapeutics Market 2018 – 2023
Global Pneumonia Therapeutics Market 2018–2023 Poised for xx% Growth Planet Market Research has recently added a market study named Global Pneumonia Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023 with prime importance on the forecast period from 2018 to 2023. The report is an in-depth analysis of the market for pneumonia therapeutics and covers various driving factors, restraints, opportunities and challenges affecting the market’s growth. Pneumonia is an
Pneumonia Drug Development Market Focuses on Top Players (Hospital Acquired Pneu …
Pneumonia Drug Development Market study provides comprehensive data which enhances the understanding, scope and application of this report. Polyamides, polyethylene, nylons, epoxy resins, polysulfones, polyphthalamides, polyesters, and polycarbonates are some key forms of plastics that are employed in electronic components. The insulation properties of plastic account for its in depth use in electrical and electronic components of machines and gadgets. Report Consultant has introduced a new report titled as Global Pneumonia
Pneumonia Testing Market Opportunity Analysis, 2018-2026
Pneumonia is a lung infection caused by bacteria, viruses or fungi, primarily affecting the small sir sacs known as alveoli. The most common bacterial type that causes pneumonia is Streptococcus pneumoniae. The symptoms for pneumonia include, fever, chills, cough, shortness of breath and fatigue. To detect whether, a person has pneumonia are blood tests, chest X-ray, pulse oximetry, and Sputum test. Further, if the patients is older than age 65,
Hospital-acquired Pneumonia Drugs Market: to reach over by 2020
Hospital-acquired Pneumonia Drugs Market: Overview Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of
Global Pneumonia Market: Industry Analysis, outlook and Forecast by 2025
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Pneumonia Market Report 2018” which provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including Merck & Co. Inc., Allergan
Pneumonia Diagnostics Market worth US$ 685 Mn by 2027
The World Health Organization estimates that pneumonia accounted for 16% of all deaths of children below the age of 5 years – more than 920,000 in 2015. The WHO states that the cost of pneumonia antibiotic treatment in the same year for child survival and newly born babies is roughly US$ 110 million annually. Therefore, there is a pressing need to analyse the pneumonia diagnostics market. In an upcoming report